来凯医药已与礼来达成合作,双巨头重新定义减肥医美

生物科技馆
26 May

近日,凯医药与礼来达成合。据悉,LAE102是来凯医药自主研发的全球首创ActRIIA单克隆抗体,旨在解决GLP-1受体激动剂减重疗法中常见的肌肉流失问题。GLP-1类药物在减重领域展现出良好的效果,但其副作用之一是导致显著的肌肉流失,影响患者的代谢健康和长期体重维持。LAE102通过靶向ActRIIA受体,有效抑制肌生成抑制素和GDF11的活性,从而促进肌肉生长、减少脂肪堆积。来凯医药与礼来达成...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10